BCIQ Profiles

Company Profile Report
0330 Pyxis series B EMB Tue 8a ET
BioCentury & Getty Images


With ADC pipeline now a top priority, Pyxis adds $152M series B

Arix joins syndicate after 12x return on ADC play VelosBio

Fresh from a strong return on its investment in VelosBio, Arix backs another antibody-drug conjugate developer.

Mar 30, 2021 | 12:01 PM GMT

Pyxis’ $152 million series B round gives the company the ability to advance

Read the full 663 word article

How to gain access

Continue reading with a
two-week free trial.